Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MAJED A KOLEILAT

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1922175694
CMS profile
178334
Location
EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$39,987.82

121 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MAJED A KOLEILAT

NPI 1922175694 · CMS profile ID 178334

Allopathic & Osteopathic Physicians / Allergy & Immunology

EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922175694?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922175694?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922175694?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MAJED A KOLEILAT, NPI 1922175694, CMS profile ID 178334, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 121 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1922175694?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

121 matching records · $39,987.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 121 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 121.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $22.2508/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114090523 CMS
Pharming Healthcare, Inc. $29.7008/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132153157 CMS
GlaxoSmithKline, LLC. $18.9308/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116132287 CMS
GlaxoSmithKline, LLC. $7.0008/02/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116544984 CMS
GlaxoSmithKline, LLC. $13.0008/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116161345 CMS
GENZYME CORPORATION $10.3507/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139709059 CMS
CSL Behring $23.0907/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134646359 CMS
AstraZeneca Pharmaceuticals LP $950.0007/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104721585 CMS
Regeneron Healthcare Solutions, Inc. $17.2207/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114090521 CMS
Amgen Inc. $14.6107/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111622638 CMS
AstraZeneca Pharmaceuticals LP $1,400.0007/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104463138 CMS
CSL Behring $18.7807/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134646357 CMS
AstraZeneca Pharmaceuticals LP $24.7907/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104242061 CMS
AstraZeneca Pharmaceuticals LP $14.8807/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105447577 CMS
Regeneron Healthcare Solutions, Inc. $98.3407/02/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114090519 CMS
Amgen Inc. $14.3606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111622636 CMS
AstraZeneca Pharmaceuticals LP $950.0006/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105482641 CMS
Regeneron Healthcare Solutions, Inc. $17.6606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114090517 CMS
AstraZeneca Pharmaceuticals LP $13.6406/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104368915 CMS
AstraZeneca Pharmaceuticals LP $2,800.0006/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105219676 CMS
Grifols USA, LLC $14.2906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124747605 CMS
AstraZeneca Pharmaceuticals LP $120.7206/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104280491 CMS
AstraZeneca Pharmaceuticals LP $39.5306/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105850058 CMS
GlaxoSmithKline, LLC. $17.6706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116479497 CMS
Hikma Pharmaceuticals USA $14.9206/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127508351 CMS
AstraZeneca Pharmaceuticals LP $950.0005/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105230417 CMS
AstraZeneca Pharmaceuticals LP $2,800.0005/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105658490 CMS
CSL Behring $17.1005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134646351 CMS
Grifols USA, LLC $13.1205/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124747607 CMS
Pharming Healthcare, Inc. $21.4505/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132153151 CMS
Regeneron Healthcare Solutions, Inc. $26.7905/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114090515 CMS
AstraZeneca Pharmaceuticals LP $38.1905/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105729973 CMS
AstraZeneca Pharmaceuticals LP $120.0005/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105870937 CMS
AstraZeneca Pharmaceuticals LP $13.1505/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104279271 CMS
GENZYME CORPORATION $13.8105/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139709095 CMS
AstraZeneca Pharmaceuticals LP $1,850.0004/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104242883 CMS
GENZYME CORPORATION $4.9304/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139709037 CMS
Regeneron Healthcare Solutions, Inc. $16.7504/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114090513 CMS
Genentech, Inc. $39.2704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133058399 CMS
GlaxoSmithKline, LLC. $19.6904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116137218 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.7104/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137605643 CMS
AstraZeneca Pharmaceuticals LP $11.9004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104595636 CMS
AstraZeneca Pharmaceuticals LP $14.7404/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104681391 CMS
AstraZeneca Pharmaceuticals LP $111.8004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105681013 CMS
GENZYME CORPORATION $27.7504/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139709039 CMS
GlaxoSmithKline, LLC. $11.1204/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116028706 CMS
Regeneron Healthcare Solutions, Inc. $11.8203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114090511 CMS
GlaxoSmithKline, LLC. $18.5903/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116625496 CMS
Genentech USA, Inc. $20.8503/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133058386 CMS
GlaxoSmithKline, LLC. $19.1903/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116523176 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22,744.84 121
PY2020 $8,447.25 86
PY2021 $11,770.23 134
PY2022 $6,074.19 136
PY2023 $10,875.95 114
PY2024 $39,987.82 121
PY2025 $21,927.61 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $100,022.72 40
PY2024 Principal investigator $81,746.74 19
PY2023 Principal investigator $105,618.27 27
PY2022 Principal investigator $114,068.39 25
PY2021 Principal investigator $113,740.20 23
PY2020 Principal investigator $60,121.14 30
PY2019 Principal investigator $15,729.05 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $154.00 12/11/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048642
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 12/11/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048644
Principal investigator 1 GlaxoSmithKline, LLC. $2,400.00 11/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111062
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 11/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048640
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $428.40 10/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048638
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,958.20 10/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048636
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,130.10 10/14/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048634
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $725.60 10/09/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048632
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 09/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048630
Principal investigator 1 GlaxoSmithKline, LLC. $7,192.00 09/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118836
Principal investigator 1 GlaxoSmithKline, LLC. $749.55 09/08/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117552
Principal investigator 1 GlaxoSmithKline, LLC. $76.42 09/03/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111070
Principal investigator 1 GlaxoSmithKline, LLC. $561.00 08/21/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111034
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/21/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111040
Principal investigator 1 GlaxoSmithKline, LLC. $106.07 08/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111047
Principal investigator 1 GlaxoSmithKline, LLC. $806.00 08/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118843
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $581.70 08/19/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048603
Principal investigator 1 GlaxoSmithKline, LLC. $3,275.60 08/01/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111076
Principal investigator 1 GlaxoSmithKline, LLC. $2,062.00 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117595
Principal investigator 1 GlaxoSmithKline, LLC. $1,620.00 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117601
Principal investigator 1 GlaxoSmithKline, LLC. $9,109.88 07/25/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192118824
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,130.10 07/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048628
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,650.00 07/23/2025 Non-covered Recipient Entity
DEACONESS CLINIC COMP CENTER MIDTOWN CAMPUS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185549593
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.40 06/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048626
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $755.00 06/19/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048624
Principal investigator 1 GlaxoSmithKline, LLC. $2,252.45 06/16/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117589
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,537.00 06/13/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048622
Principal investigator 1 GlaxoSmithKline, LLC. $869.25 05/05/2025 Non-covered Recipient Entity
DEACONESS CLINIC GIBSON HOSPITAL
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192111053
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,640.15 04/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC COMP CENTER MIDTOWN CAMPUS
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185549591
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,889.50 04/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048620
Principal investigator 1 GlaxoSmithKline, LLC. $965.20 04/04/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117572
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,126.80 03/20/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048618
Principal investigator 1 GlaxoSmithKline, LLC. $1,092.00 03/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117577
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,163.40 02/27/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048615
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/24/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048672
Principal investigator 1 GlaxoSmithKline, LLC. $1,914.00 02/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117560
Principal investigator 1 GlaxoSmithKline, LLC. $915.00 02/07/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117583
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,112.80 01/30/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048613
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,327.10 01/16/2025 Non-covered Recipient Entity
DEACONESS CLINIC INC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048611
Principal investigator 1 GlaxoSmithKline, LLC. $1,133.35 01/13/2025 Non-covered Recipient Entity
DEACONESS HOSPITAL PHS
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192117566